Edition:
United Kingdom

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

10.81USD
18 Jan 2019
Change (% chg)

$0.22 (+2.08%)
Prev Close
$10.59
Open
$10.65
Day's High
$11.02
Day's Low
$10.65
Volume
78,948
Avg. Vol
117,608
52-wk High
$26.05
52-wk Low
$8.29

Latest Key Developments (Source: Significant Developments)

Oppenheimerfunds Inc Reports 10.28 Pct Passive Stake In Glycomimetics
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - GlycoMimetics Inc ::OPPENHEIMERFUNDS, INC REPORTS 10.28 PERCENT PASSIVE STAKE IN GLYCOMIMETICS INC AS OF AUGUST 31 - SEC FILING.  Full Article

Glycomimetics Says Pfizer Sees Top Line Data Available In Q2 For Ongoing Phase 3 Trial With Rivipansel
Wednesday, 25 Jul 2018 

July 25 (Reuters) - GlycoMimetics Inc ::GLYCOMIMETICS SAYS ON JULY 23, NOTIFIED BY PFIZER THAT PFIZER NOW SEES TOP LINE DATA AVAILABLE IN Q2 OF 2019 FOR ONGOING PHASE 3 TRIAL WITH RIVIPANSEL.  Full Article

GlycoMimetics Announces NCI-Sponsored Pivotal Trial Of GMI-1271 In Older, Newly Diagnosed AML Patients Fit For Intensive Chemotherapy
Wednesday, 30 May 2018 

May 30 (Reuters) - GlycoMimetics Inc ::GLYCOMIMETICS ANNOUNCES NCI-SPONSORED PIVOTAL TRIAL OF GMI-1271 IN OLDER, NEWLY DIAGNOSED AML PATIENTS FIT FOR INTENSIVE CHEMOTHERAPY.GLYCOMIMETICS INC - UNDER TERMS OF CRADA, NCI MAY ALSO FUND ADDITIONAL RESEARCH.GLYCOMIMETICS INC - CO TO SUPPLY GMI-1271 AS WELL AS PROVIDE FINANCIAL SUPPORT TO AUGMENT DATA ANALYSIS AND MONITORING FOR PHASE 3 PROGRAM.GLYCOMIMETICS INC - ANNOUNCED THAT GENERIC NAME FOR GMI-1271 WILL BE UPROLESELAN.  Full Article

GlycoMimetics qtrly loss per share $‍0.24
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and third quarter 2017 results.Glycomimetics inc - ‍phase 3 clinical trial of rivipansel on track for completion in second half of 2018​.Glycomimetics inc qtrly loss per share $‍0.24​.Glycomimetics inc - ‍research and development expenses decreased slightly to $5.8 million for quarter ended september 30, 2017 as compared to $5.9 million​.  Full Article